Cargando…

Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression

The human epidermal growth factor receptor 2 (Her2) is tested in many human cancers, including breast, bladder, pancreatic, ovarian and stomach. The American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) have issued Clinical Practice Guidelines for reporting Her2 results...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quddus, M. Ruhul, Hansen, Katrine, Tantravahi, Umadevi, Sung, C. James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103767/ https://www.ncbi.nlm.nih.gov/pubmed/32258332 http://dx.doi.org/10.1016/j.gore.2020.100561

Ejemplares similares

Low-level expression of human Epidermal growth Factor Receptor-2 (HER2) in High-Grade Mullerian Tumors: Implications for therapy decision making
por: Abada, Evi, et al.
Publicado: (2023)

Molecular markers in uterine serous cancer: Correlation between endometrial biopsy and hysterectomy specimens
por: Lokich, Elizabeth, et al.
Publicado: (2019)

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023)

"Surface epithelial changes" in uterine endometrioid carcinoma mimicking micropapillary serous borderline tumor of ovary: report of two cases and review of the literature
por: Singh, Kamaljeet, et al.
Publicado: (2011)

COL1A1-PDGFB fusion uterine fibrosarcoma: A case report with treatment implication
por: Grindstaff, Samuel L., et al.
Publicado: (2019)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Simultaneous p53 and KRAS mutation in a high-grade serous carcinoma with deceptive appearance of a low-grade carcinoma. A case report
por: Marketkar, Shivali, et al.
Publicado: (2023)

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management
por: Lopez, Salvatore, et al.
Publicado: (2018)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Clinicopathological Characteristics and Her-2/neu Status in Chinese Patients with Uterine Papillary Serous Carcinoma
por: Ren, Yulan, et al.
Publicado: (2011)

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
por: English, Diana P, et al.
Publicado: (2014)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
por: ElSahwi, Karim S., et al.
Publicado: (2011)

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Combined trastuzumab and radiation therapy for HER2-positive uterine serous carcinoma: A case report
por: Mao, SPH, et al.
Publicado: (2023)

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications
por: Iqbal, Nida, et al.
Publicado: (2014)

COL1A1-PDGFB fusion uterine sarcoma and its response to Imatinib therapy
por: Grindstaff, Samuel L., et al.
Publicado: (2020)

Malignant Pleural Effusion Due to Uterine Serous Carcinoma: An Unusual Presentation
por: Wasifuddin, Mustafa, et al.
Publicado: (2023)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

The expression of selenium-binding protein 1 is decreased in uterine leiomyoma
por: Zhang, Peng, et al.
Publicado: (2010)

A Rapidly Enlarging Squamous Inclusion Cyst in an Axillary Lymph Node following Core Needle Biopsy
por: Zhang, Cunxian, et al.
Publicado: (2012)

Liesegang-Like Rings in Lactational Changes in the Breast
por: Islam, Mohd T., et al.
Publicado: (2012)

Changes in the detection of human epidermal growth factor receptor 2 gene (Her-2) status for Her-2 fluorescent in situ hybridization testing
por: Xu, Ying, et al.
Publicado: (2022)

Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients’ Clinical Features
por: Li, Wei, et al.
Publicado: (2018)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Towards comprehensive characterization of HER2 overexpression
por: Berezov, Alan, et al.
Publicado: (2006)

MicroRNA and HER2-overexpressing Cancer
por: Wang, Shizhen Emily, et al.
Publicado: (2013)

Clear Cell Carcinomas of the Mullerian System: Does the Pathogenesis Vary Depending on Their Nuclear Grade and Their Association with Endometriosis? An Immunohistochemical Analysis
por: Alduaij, Ahmad, et al.
Publicado: (2012)

An Unusual Case of Stevens-Johnson/Toxic Epidermal Necrolysis Overlap Syndrome in HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer Patient Treated With Docetaxel
por: Shamloul, Gelan, et al.
Publicado: (2023)

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2020)

Rare brain metastasis with unusual characteristics in a late recurrence of stage IIIA uterine papillary serous carcinoma
por: Crain, Charles Nicolas, et al.
Publicado: (2021)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_eu7p4ctce4na5rns42b1hsq56o